Preoperative 18F-FDG PET/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer.
Adult
Aged
Aged, 80 and over
Endometrial Neoplasms
/ diagnosis
Female
Fluorodeoxyglucose F18
/ pharmacology
Humans
Lymph Nodes
/ diagnostic imaging
Lymphatic Metastasis
Magnetic Resonance Imaging
/ methods
Male
Middle Aged
Positron Emission Tomography Computed Tomography
/ methods
Positron-Emission Tomography
/ methods
ROC Curve
Radiopharmaceuticals
/ pharmacology
18F-FDG
Endometrial cancer
Lymphatic metastasis
Magnetic resonance imaging
PET-CT
Journal
European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
14
08
2019
accepted:
12
12
2019
revised:
15
11
2019
pubmed:
9
2
2020
medline:
21
10
2020
entrez:
9
2
2020
Statut:
ppublish
Résumé
To compare the diagnostic accuracy of preoperative 18F-FDG PET/CT and MRI tumor markers for prediction of lymph node metastases (LNM) and aggressive disease in endometrial cancer (EC). Preoperative whole-body 18F-FDG PET/CT and pelvic MRI were performed in 215 consecutive patients with histologically confirmed EC. PET/CT-based tumor standardized uptake value (SUV For prediction of LNM, MTV yielded the largest area under the ROC curve (AUC) (AUC = 0.80), whereas V Tumor markers from 18F-FDG PET/CT outperform MRI markers for the prediction of LNM. MTV > 27 ml yields a high diagnostic performance for predicting aggressive disease and represents a promising supplement to conventional PET/CT reading in EC. • Metabolic tumor volume (MTV) outperforms other 18F-FDG PET/CT and MRI markers for preoperative prediction of lymph node metastases (LNM) in endometrial cancer patients. • Using cutoff values for tumor volume for prediction of LNM, MTV > 27 ml yielded higher specificity and accuracy than V
Identifiants
pubmed: 32034487
doi: 10.1007/s00330-019-06622-w
pii: 10.1007/s00330-019-06622-w
pmc: PMC7160067
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2443-2453Subventions
Organisme : Helse Vest
ID : 912060
Organisme : Bergens Forskningsstiftelse
ID : BFS2018TMT06
Références
Gynecol Oncol. 2012 Jul;126(1):5-11
pubmed: 22555109
Lancet. 2009 Jan 10;373(9658):125-36
pubmed: 19070889
BJOG. 2014 Aug;121(9):1097-106; discussion 1106
pubmed: 24397772
Ann Nucl Med. 2016 Feb;30(2):104-13
pubmed: 26546334
Int J Gynaecol Obstet. 2009 May;105(2):109
pubmed: 19345353
Radiology. 2017 May;283(2):450-459
pubmed: 28051912
J Clin Oncol. 2012 Apr 20;30(12):1329-34
pubmed: 22412131
J Nucl Med. 2016 Jun;57(6):879-85
pubmed: 26823564
J Natl Cancer Inst. 2008 Dec 3;100(23):1707-16
pubmed: 19033573
Int J Gynecol Cancer. 2010 Nov;20(8):1350-5
pubmed: 21051976
Curr Oncol Rep. 2016 Apr;18(4):25
pubmed: 26922331
J Gynecol Oncol. 2017 Nov;28(6):e78
pubmed: 29027396
J Nucl Med. 2015 Aug;56(8):1191-8
pubmed: 26045311
Cancer. 1987 Oct 15;60(8 Suppl):2035-41
pubmed: 3652025
Eur J Cancer. 2016 Jul;61:52-60
pubmed: 27153472
Int J Gynecol Cancer. 2015 Mar;25(3):459-66
pubmed: 25628109
Int J Gynecol Cancer. 2013 Nov;23(9):1536-43
pubmed: 24172090
Radiother Oncol. 2015 Dec;117(3):559-81
pubmed: 26683800
Am J Obstet Gynecol. 2003 May;188(5):1265-72
pubmed: 12748496
Radiology. 2018 Apr;287(1):176-184
pubmed: 29185901
Int J Gynecol Cancer. 2018 Jun;28(5):869-874
pubmed: 29557824
Am J Obstet Gynecol. 2012 Sep;207(3):197.e1-8
pubmed: 22939725
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
World J Surg Oncol. 2018 May 17;16(1):95
pubmed: 29773071
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
Gynecol Oncol. 2013 Oct;131(1):103-8
pubmed: 23845691
Gynecol Oncol. 2018 Mar;148(3):491-498
pubmed: 29273307